Antibody against transporter and use thereof
AssigneesKinki University, Link Genomics, Inc.
InventorsTakashi Masuko, Shinichiro Niwa, Hidemi Hayashi, Dai Ogura, Takayuki Shindou
Life of this patent
Estimating the term…
Abstract
The present invention provides a prophylactic or therapeutic agent for various malignant tumors, including currently intractable solid tumors, which contains a novel antibody having the ability to bind to human LAT1/CD98 and inducing antibody-dependent cellular cytotoxicity specifically against cancer cells as an active ingredient.
Claims35
An antibody or an antigen-binding fragment thereof, each specifically binding to the extracellular region of the LAT1/CD98 complex in LAT1/CD98-expressing cells, which is:
- (1) an antibody or an antigen-binding fragment thereof, which comprises, as light chain complementarity determining region 1 (CDRL1), light chain complementarity determining region 2 (CDRL2) and light chain complementarity determining region 3 (CDRL3), the amino acid sequences of SEQ ID NO:
- 7, SEQ ID NO:
- 8 and SEQ ID NO:
- 9, respectively, or amino acid sequences modified to have mutation of one or several amino acid residues in the amino acid sequences of SEQ ID NO:
- 7, SEQ ID NO:
- 8 and SEQ ID NO:
- 9, respectively, and
- which comprises, as heavy chain complementarity determining region 1 (CDRH1), heavy chain complementarity determining region 2 (CDRH2) and heavy chain complementarity determining region 3 (CDRH3), the amino acid sequences of SEQ ID NO:
- 10, SEQ ID NO:
- 11 and SEQ ID NO:
- 12, respectively, or amino acid sequences modified to have mutation of one or several amino acid residues in the amino acid sequences of SEQ ID NO:
- 10, SEQ ID NO:
- 11 and SEQ ID NO:
- 12, respectively;
- (2) an antibody or an antigen-binding fragment thereof, which comprises, as CDRL1, CDRL2 and CDRL3, the amino acid sequences of SEQ ID NO:
- 13, SEQ ID NO:
- 14 and SEQ ID NO:
- 15, respectively, or amino acid sequences modified to have mutation of one or several amino acid residues in the amino acid sequences of SEQ ID NO:
- 13, SEQ ID NO:
- 14 and SEQ ID NO:
- 15, respectively, and
- which comprises, as CDRH1, CDRH2 and CDRH3, the amino acid sequences of SEQ ID NO:
- 16, SEQ ID NO:
- 17 and SEQ ID NO:
- 18, respectively, or amino acid sequences modified to have mutation of one or several amino acid residues in the amino acid sequences of SEQ ID NO:
- 16, SEQ ID NO:
- 17 and SEQ ID NO:
- 18, respectively;
- (3) an antibody or an antigen-binding fragment thereof, which comprises, as CDRL1, CDRL2 and CDRL3, the amino acid sequences of SEQ ID NO:
- 19, SEQ ID NO:
- 20 and SEQ ID NO:
- 21, respectively, or amino acid sequences modified to have mutation of one or several amino acid residues in the amino acid sequences of SEQ ID NO:
- 19, SEQ ID NO:
- 20 and SEQ ID NO:
- 21, respectively, and
- which comprises, as CDRH1, CDRH2 and CDRH3, the amino acid sequences of SEQ ID NO:
- 22, SEQ ID NO:
- 23 and SEQ ID NO:
- 24, respectively, or amino acid sequences modified to have mutation of one or several amino acid residues in the amino acid sequences of SEQ ID NO:
- 22, SEQ ID NO:
- 23 and SEQ ID NO:
- 24, respectively;
- or
- (4) an antibody or an antigen-binding fragment thereof, which comprises, as CDRL1, CDRL2 and CDRL3, the amino acid sequences of SEQ ID NO:
- 25, SEQ ID NO:
- 26 and SEQ ID NO:
- 27, respectively, or amino acid sequences modified to have mutation of one or several amino acid residues in the amino acid sequences of SEQ ID NO:
- 25, SEQ ID NO:
- 26 and SEQ ID NO:
- 27, respectively, and
- which comprises, as CDRH1, CDRH2 and CDRH3, the amino acid sequences of SEQ ID NO:
- 28, SEQ ID NO:
- 29 and SEQ ID NO:
- 30, respectively, or amino acid sequences modified to have mutation of one or several amino acid residues in the amino acid sequences of SEQ ID NO:
- 28, SEQ ID NO:
- 29 and SEQ ID NO:
- 30, respectively.
An antibody or an antigen-binding fragment thereof, each specifically binding to the extracellular region of the LAT1/CD98 complex in LAT1/CD98-expressing cells, which comprises:
- (1) light chain complementarity determining region 1 (CDRL1) comprising the amino acid sequence X1ASQX2VGNNVA (SEQ ID NO:
- 1);
- (2) light chain complementarity determining region 2 (CDRL2) comprising the amino acid sequence YASX3RX4T (SEQ ID NO:
- 2);
- (3) light chain complementarity determining region 3 (CDRL3) comprising the amino acid sequence QRX5YKSPYT (SEQ ID NO:
- 3);
- (4) heavy chain complementarity determining region 1 (CDR 1) comprising the amino acid sequence GFSLPTSSVS (SEQ ID NO:
- 4);
- (5) heavy chain complementarity determining region 2 (CDRH2) comprising the amino acid sequence VIWSNGNTDYSSX6X7KS (SEQ ID NO:
- 5);
- and
- (6) heavy chain complementarity determining region 3 (CDRH3) comprising the amino acid sequence NFRNX8PGVMDA (SEQ ID NO:
- 6)
- (provided that X1 to X8 are each any naturally occurring amino acid residue).
A complementarity determining region (CDR), which is selected from the group consisting of (1) to (6) shown below:
- (1) light chain complementarity determining region 1 (CDRL1) comprising the amino acid sequence of SEQ ID NO:
- 7, 13, 19 or 25;
- (2) light chain complementarity determining region 2 (CDRL2) comprising the amino acid sequence of SEQ ID NO:
- 8, 14, 20 or 26;
- (3) light chain complementarity determining region 3 (CDRL3) comprising the amino acid sequence of SEQ ID NO:
- 9, 15, 21 or 27;
- (4) heavy chain complementarity determining region 1 (CDRH1) comprising the amino acid sequence of SEQ ID NO:
- 10, 16, 22 or 28;
- (5) heavy chain complementarity determining region 2 (CDRH2) comprising the amino acid sequence of SEQ ID NO:
- 11, 17, 23 or 29;
- and
- (6) heavy chain complementarity determining region 3 (CDRH3) comprising the amino acid sequence of SEQ ID NO:
- 12, 18, 24 or 30.
Dependencies are inferred from the claim text.